SLNO (Soleno Therapeutics Inc) Earnings per share for the last four quarters

Soleno (SLNO) - corporate logo

Strong pricing power in the orphan drug segment allows Soleno Therapeutics (SLNO) to dictate payment terms, which is reflected in the historical percentage growth of EPS YoY (ttm), where the current metric equals 139.20. The business relies on an asset-light model with outsourced production, and its success is independent of economic cycles, basing itself exclusively on the clinical trial results of new drugs.

SLNO soleno.life Net earnings per share (EPS TTM) (02/11/2024 - 05/30/2026)

SLNO (Soleno Therapeutics): analytical breakdowns and indicator data

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:SLNO (Soleno Therapeutics Inc)
Core merchandise of Soleno Therapeutics Corp

For Soleno Therapeutics (SLNO), which monetizes exclusivity in the treatment of Prader-Willi syndrome, this indicator measures the rate of change in net earnings per share over a rolling year, revealing hidden shifts in fundamental value. By analyzing the annual EPS TTM growth rate, an investor can assess the business's resilience to market volatility, recognizing that even an upward trend does not eliminate the risk of a sharp capital correction.

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|MDGL (Madrigal Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|CORT: Earnings per share for the last four quarters|RYTM (Rhythm Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Akero Therapeutics|Net earnings per share (EPS TTM) MTSR|Earnings per share for the last twelve months MLTX (MoonLake Immunotherapeutics AG)|Earnings per share for the last twelve months crinetics.com CRNX|NewAmsterdam Pharma Corp (NAMS) - Net earnings per one share for the last twelve months|FOLD - Earnings per share for the last twelve months|ETNB: Earnings per share for the last twelve months|AGIO: Net earnings per share (EPS TTM)|GPCR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months MiMedx Corp|Rezolute Bio (RZLT) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months lexpharma.com (LXRX)|Net earnings per share for the last 12 months MBX Biosciences Inc MBX|Earnings per share for the last twelve months Altimmune ALT|Net earnings per share (EPS TTM) Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BioAge Labs, Inc BIOA|Biomea Fusion Inc (BMEA) - Earnings per share for the last twelve months|QNCX - Net earnings per share for the last four quarters|GUTS (Fractyl Health Inc.) - Net earnings per share (EPS TTM)|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS